Basic information
- CAS
66644-81-3- Standard SMILES
C=CCN1CCCC1CNC(=O)c1cc(S(N)(=O)=O)cc(OC)c1OC- InChIKey
RYJXBGGBZJGVQF-UHFFFAOYSA-N- Molecular formula
- C17H25N3O5S
- Average molar mass
- 383.5 g/mol
- Monoisotopic mass
- 383.15149208
Overview
Veralipride is a sulfonamide.
Names & identifiers
- Preferred name
- Veralipride
- IUPAC
- 2,3-dimethoxy-N-[(1-prop-2-enylpyrrolidin-2-yl)methyl]-5-sulfamoylbenzamide
- English name
- N-(1-Allyl-2-pyrrolidinyl)methyl-2,3-dimethoxy-5-sulfamoylbenzamide
- Molecular formula
- C17H25N3O5S
- Molecular weight
- 383.46
Names & synonyms
VERALIPRIDE66644-81-3AgrealAgradilVeralipridaVeralipridumDTXSID6046268S7064109UDDTXCID4026268N-(1-allyl-2-pyrrolidinyl)methyl-2,3-dimethoxy-5-sulfamoylbenzamide2,3-dimethoxy-N-{[1-(prop-2-en-1-yl)pyrrolidin-2-yl]methyl}-5-sulfamoylbenzamide2,3-dimethoxy-N-((1-(prop-2-en-1-yl)pyrrolidin-2-yl)methyl)-5-sulfamoylbenzamide
Show more names
LIR166VelariprideVeralipride, 10 mM in DMSON-[(1-Allyl-2-pyrrolidinyl)methyl]-5-sulphamoyl-2-veratramideLIR 166,inhibit,Dopamine Receptor,Veralipride,Inhibitor,LIR-166N-[(1-Allylpyrrolidin-2-yl)methyl]-2,3-dimethoxy-5-sulfamoylbenzamideBenzamide, 5-(aminosulfonyl)-2,3-dimethoxy-N-[[1-(2-propen-1-yl)-2-pyrrolidinyl]methyl]-
RefChem:193953N05AL06266-435-5Veralipride [INN]LIR 16602,3-dimethoxy-N-[(1-prop-2-enylpyrrolidin-2-yl)methyl]-5-sulfamoylbenzamideVeralipridum [INN-Latin]Veraliprida [INN-Spanish]
Properties
Computed structural properties
- XLogP
- 0.8
- Topological polar surface area
- 119 Ų
- Hydrogen bond donors
- 2
- Hydrogen bond acceptors
- 7
- Rotatable bonds
- 8
- Heavy atoms
- 26
- Formal charge
- 0
- Complexity
- 592
Experimental & physicochemical properties
LogP1.47
Physicochemical properties
- Melting point
- 128 °C · 128 °C
- Density
- 1.23 · 1.230±0.06 g/cm3(Predicted)
- storage temp.
- 2 · under inert gas (nitrogen or Argon) at 2-8°C
- solubility
- Chloroform (Slightly), DMSO (Slightly)
- form
- Solid
- pka
- 10.02 · 10.02±0.60(Predicted)
- color
- White to Off-White
- FDA UNII
- 7064109 UD · S7064109UD
- ATC code
- 5 AL06 · N05AL06
- Symbol(GHS)
- 7 · GHS07
- Signal word
- Warning
- Hazard statements
- 312 · H312-H302-H332
- Precautionary statements
- 264 · P264-P270-P301+P312-P330-P501-P261-P271-P304+P340-P312-P280-P302+P352-P312-P322-P363-P501
Safety & regulation
Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
GHS classification
GHS Classification
Warning
H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]
P261, P264, P270, P271, P280, P301+P317, P302+P352, P304+P340, P317, P321, P330, P362+P364, and P501 (click each P-code to see the statement)
The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.
Safety data
- hs_code
- 2935.90.6000
- Signal word
- Warning
- Symbol(GHS)
- GHS07
- Hazard statements
- H312-H302-H332
- Precautionary statements
- P264-P270-P301+P312-P330-P501-P261-P271-P304+P340-P312-P280-P302+P352-P312-P322-P363-P501
Chemistry & industry
Pharmacology
ATC CodeN - Nervous system
MeSH Pharmacological Classification
Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus.
Applications
UsesVeralipride, a synthetic benzamide derivative with antidopaminergic action, is effective in reducing the frequency and severity of hot flashes associated with menopausal hypoestrogenism, gaining interest as a non-hormonal treatment for climacteric flushing.
UsesLabelled Veralipride, a synthetic benzamide derivative with antidopaminergic action, is effective in reducing the frequency and severity of hot flashes associated with menopausal hypoestrogenism, gain ing interest as a non-hormonal treatment for climacteric flushing.
Upstream & downstream products
Upstream raw materials
Related reactions
0 records
No reaction records under the current filter.
Compound notes
Loading…